{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T16:42:39Z","timestamp":1770741759951,"version":"3.49.0"},"reference-count":22,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>COVID\u201019 is a novel infectious disease with a broad spectrum of clinical severity. Patients with systemic vasculitis have an increased risk of serious infections and may be at risk of severe outcomes following COVID\u201019. We undertook this study to establish the risk factors for severe COVID\u201019 outcomes in these patients, including the impact of immunosuppressive therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicenter cohort was developed through the participation of centers affiliated with national UK and Ireland vasculitis registries. Clinical characteristics and outcomes are described. Logistic regression was used to evaluate associations between potential risk factors and a severe COVID\u201019 outcome, defined as a requirement for advanced oxygen therapy, a requirement for invasive ventilation, or death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The cohort included 65 patients with systemic vasculitis who developed COVID\u201019 (median age 70 years, 49% women), of whom 25 patients (38%) experienced a severe outcome. Most patients (55 of 65 [85%]) had antineutrophil cytoplasmic antibody\u2013associated vasculitis (AAV). Almost all patients required hospitalization (59 of 65 [91%]), 7 patients (11%) were admitted to intensive care, and 18 patients (28%) died. Background glucocorticoid therapy was associated with severe outcomes (adjusted odds ratio [OR] 3.7 [95% confidence interval 1.1\u201314.9]; <jats:italic>P<\/jats:italic> = 0.047), as was comorbid respiratory disease (adjusted OR 7.5 [95% confidence interval 1.9\u201338.2]; <jats:italic>P<\/jats:italic> = 0.006). Vasculitis disease activity and nonglucocorticoid immunosuppressive therapy were not associated with severe outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with systemic vasculitis, glucocorticoid use at presentation and comorbid respiratory disease were associated with severe outcomes in COVID\u201019. These data can inform clinical decision\u2010making relating to the risk of severe COVID\u201019 in this vulnerable patient group.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.41728","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T08:11:57Z","timestamp":1616400717000},"page":"1713-1719","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID\u201019: A Binational, Registry\u2010Based Cohort Study"],"prefix":"10.1002","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5626-2470","authenticated-orcid":false,"given":"Matthew A.","family":"Rutherford","sequence":"first","affiliation":[{"name":"University of Glasgow and Queen Elizabeth University Hospital  Glasgow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Scott","sequence":"additional","affiliation":[{"name":"Trinity College Dublin  Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira","family":"Karabayas","sequence":"additional","affiliation":[{"name":"NHS Grampian  Aberdeen UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6653-7511","authenticated-orcid":false,"given":"Marilina","family":"Antonelou","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1584-6186","authenticated-orcid":false,"given":"Seerapani","family":"Gopaluni","sequence":"additional","affiliation":[{"name":"University of Cambridge  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gray","sequence":"additional","affiliation":[{"name":"University of Oxford  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Barrett","sequence":"additional","affiliation":[{"name":"University of Oxford  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke R.","family":"Brix","sequence":"additional","affiliation":[{"name":"Manchester University NHS Foundation Trust and University of Manchester  Manchester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9128-6603","authenticated-orcid":false,"given":"Neeraj","family":"Dhaun","sequence":"additional","affiliation":[{"name":"University of Edinburgh  Edinburgh UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-8770","authenticated-orcid":false,"given":"Stephen P.","family":"McAdoo","sequence":"additional","affiliation":[{"name":"Hammersmith Hospital and Imperial College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rona M.","family":"Smith","sequence":"additional","affiliation":[{"name":"University of Cambridge  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin\u00a0C.","family":"Geddes","sequence":"additional","affiliation":[{"name":"Queen Elizabeth University Hospital  Glasgow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[{"name":"University of Cambridge  Cambridge UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raashid","family":"Luqmani","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan D.","family":"Salama","sequence":"additional","affiliation":[{"name":"University College London and Royal Free Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Little","sequence":"additional","affiliation":[{"name":"Trinity College Dublin  Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-3145","authenticated-orcid":false,"given":"Neil","family":"Basu","sequence":"additional","affiliation":[{"name":"University of Glasgow  Glasgow UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the UK and Ireland Vasculitis Rare Disease Group (UKIVAS)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"e_1_2_7_3_1","unstructured":"World Health Organization.WHO Director\u2010General\u2019s opening remarks at the media briefing on COVID\u201019\u201311 March 2020. URL:https:\/\/www.who.int\/dg\/speeches\/detail\/who\u2010director\u2010general\u2010s\u2010opening\u2010remarks\u2010at\u2010the\u2010media\u2010briefing\u2010on\u2010covid\u201019\u2010\u2010\u201011\u2010march\u20102020."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa035"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803537"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2011-000523"},{"key":"e_1_2_7_8_1","unstructured":"COVID\u201019 Global Rheumatology Alliance. URL:https:\/\/rheum\u2010covid.org\/."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.18"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37715"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217871"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","unstructured":"The OpenSAFELY Collaborative WilliamsonE WalkerAJ BhaskaranKJ BaconS BatesC et al.OpenSAFELY: factors associated with COVID\u201019\u2010related hospital death in the linked electronic health records of 17 million adult NHS patients[preprint]. medRxiv. May2020. URL:https:\/\/doi.org\/10.1101\/2020.05.06.20092999.","DOI":"10.1101\/2020.05.06.20092999"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.1"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2648"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa829"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106096"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2020.05.012"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217877"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1985"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0204-y"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217960"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202750"},{"key":"e_1_2_7_23_1","unstructured":"Gov.UK Coronavirus (COVID\u201019) in the UK. URL:https:\/\/coronavirus.data.gov.uk\/details\/cases."}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41728","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/art.41728","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.41728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:18:13Z","timestamp":1759940293000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.41728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1002\/art.41728"],"URL":"https:\/\/doi.org\/10.1002\/art.41728","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,27]]},"assertion":[{"value":"2020-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}